Last reviewed · How we verify

NCT03887247

Reducing Concurrent Opioid-Benzodiazepine Prescriptions

Status unknown NA Last updated 19 May 2021
What this trial tests

NA trial testing E-mail Alert in Adverse Drug Effect of Opioids in 2,234 participants. Status unknown.

Timeline
6 June 2019
Primary endpoint
29 July 2021
1 June 2022

Quick facts

Lead sponsorWalter Reed National Military Medical Center
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposeother
Enrollment2,234
Start date6 June 2019
Primary completion29 July 2021
Estimated completion1 June 2022
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Walter Reed National Military Medical Center

Who can join

18 and older, any sex, with Adverse Drug Effect of Opioids or Adverse Drug Effect of Benzodiazepines. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this effort is to use informative e-mails to improve the process of prescribing of opioids and benzodiazepines within the National Capital Region/Military Health System (NCR/MHS), with the aim of decreasing concurrent opioid and benzodiazepine prescribing.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Effect of Pharmacist Email Alerts on Concurrent Prescribing of Opioids and Benzodiazepines by Prescribers and Primary Care Managers: A Randomized Clinical Trial.
    Sacarny A, Safran E, Steffel M, Dunham JR, et al · · 2022 · cited 4× · PMID 36218952 · DOI 10.1001/jamahealthforum.2022.3378

Verify or expand the search:

Other Walter Reed National Military Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03887247.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing